Finnegan client Alzheon convinced the Federal Circuit to affirm a finding issued last year by the Patent Trial and Appeal Board (PTAB) that took away a Chinese rival company’s patent covering a way of using a type of sulfonic acid to potentially treat Alzheimer’s disease.
The Federal Circuit struck down an appeal from Risen (Suzhou) Pharma Tech, a Shanghai-based startup.
Mark Feldstein told Law360 that the patent rejected by the board had covered "an obvious deuterated copy" of a sulfonic compound that Alzheon had landed its own patents on, and which is currently being clinically tested to possibly treat Alzheimer's disease.
